Pharmaceutical Executive-11-01-2018

Pharmaceutical Executive

Pharm Exec's 2019 Pipeline Report

November 23, 2018

Features

38

11

As CAR-T therapy eyes new territory-solid tumors-and expands into autoimmune disease, other frontiers in drug development are beginning to open up. They highlight the raw promise of science, with cannabis-based agents targeting CNS and rare genetic disorders, as well as the larger responsibility to public health, including advancing non-opioid alternatives, addressing antibiotic, and untangling the path to market for biosimilars.

Biopharma Business Check

November 14, 2018

Features

38

11

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.

Steadying the Path of Good Science

November 12, 2018

From the Editor

38

11

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

Southeast Biotech: Rising Tall in the Valley

November 11, 2018

Features

38

11

Pharm Exec examines the booming life sciences scene in southeast Virginia and Raleigh-Durham and Winston-Salem, North Carolina-and the region’s advantages in location, talent, and funding compared to the more glamour spots up north.

Pharmaceutical Executive, November 2018 Issue (PDF)

November 01, 2018

Issue PDF

38

11

Click the title above to open the Pharmaceutical November 2018 issue in an interactive PDF format.

Country Report: Algeria

November 01, 2018

Special Sponsored Section

38

11

Despite a recent whirlwind of changes and policy reshuffling in Algeria’s life science space, the nation’s marketplace remains a high priority for multinationals investing in the Middle East and North Africa (MENA).